ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 9 May 2008
Endocrine-Related Cancer (2008) In press
DOI: 10.1677/ERC-07-0213
Copyright © 2008 by the Society for Endocrinology.
This Article
Right arrow Accepted manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Heng, H. L.
Right arrow Articles by Gopalan, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heng, H. L.
Right arrow Articles by Gopalan, G.

RESEARCH

Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells

Hong Lee Heng, Yansong Zhu, Karthik Govindasamy and Ganesan Gopalan

H Heng, Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore
Y Zhu, Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore
K Govindasamy, Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore
G Gopalan, Cellular and Molecular Research, National Cancer Centre, Singapore, 169610, Singapore

Correspondence: Ganesan Gopalan, Email: cmrgop{at}nccs.com.sg

Abstract

Estrogen is known to play a causative role in the development of sporadic breast cancers and chemoresistance. However, studies on the mechanism and proteins involved in mediating the oncogenic effects of estrogen are very limited. Recently, Aurora-A, a centrosomal protein kinase, which induces centrosome amplification and genomic instability, was shown to be upregulated during long-term treatment of rats with estrogen and was implicated in estrogen-induced oncogenesis. Herein, we present results of the studies carried out in short term in vitro cultures to understand the regulation of Aurora-A by estrogen and the effect of downregulation of Aurora-A on estrogen-induced breast tumorigenesis and chemoresistance. Treatment of breast cancer cells with 10 nM 17-β estradiol (E2) resulted in the upregulation of Aurora-A levels in an ER-dependent manner. However, the upregulation by E2 was not restricted to Aurora-A alone suggesting that the spike in Aurora-A levels could be an indirect consequence of estrogen-mediated cell proliferation. Thus, at least in short term in vitro studies, Aurora-A is not a specific, direct target of estrogen. However, downregulation of Aurora-A by short RNA interference, led to a significant decrease in estrogen-induced, anchorage-dependent and independent growth of MCF7 cells. Moreover, knockdown of Aurora-A could overcome estrogen-induced decrease in docetaxel (Doc) sensitivity of MCF7 cells. Cumulatively, we propose that the up-regulation of Aurora-A by estrogen in short-term in vitro cultures is an indirect consequence of estrogen-induced cell proliferation. Nevertheless, Aurora-A inhibitors could be exploited to override the effects of estrogen on breast tumorigenesis and chemoresistance.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the Society for Endocrinology.